Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6KSM

Staphylococcus aureus lipase -Orlistat complex

Summary for 6KSM
Entry DOI10.2210/pdb6ksm/pdb
Related6KSI 6KSL
DescriptorLipase 2, ZINC ION, CALCIUM ION, ... (8 entities in total)
Functional Keywordsorlistat binding, hydrolase
Biological sourceStaphylococcus aureus
Total number of polymer chains2
Total formula weight94095.22
Authors
Kitadokoro, K.,Tanaka, M.,Kamitani, S. (deposition date: 2019-08-24, release date: 2020-04-08, Last modification date: 2023-11-22)
Primary citationKitadokoro, K.,Tanaka, M.,Hikima, T.,Okuno, Y.,Yamamoto, M.,Kamitani, S.
Crystal structure of pathogenic Staphylococcus aureus lipase complex with the anti-obesity drug orlistat.
Sci Rep, 10:5469-5469, 2020
Cited by
PubMed Abstract: Staphylococcus aureus lipase (SAL), a triacylglycerol esterase, is an important virulence factor and may be a therapeutic target for infectious diseases. Herein, we determined the 3D structure of native SAL, the mutated S116A inactive form, and the inhibitor complex using the anti-obesity drug orlistat to aid in drug development. The determined crystal structures showed a typical α/β hydrolase motif with a dimeric form. Fatty acids bound near the active site in native SAL and inactive S116A mutant structures. We found that orlistat potently inhibits SAL activity, and it covalently bound to the catalytic Ser116 residue. This is the first report detailing orlistat-lipase binding. It provides structure-based information on the production of potent anti-SAL drugs and lipase inhibitors. These results also indicated that orlistat can be repositioned to treat bacterial diseases.
PubMed: 32214208
DOI: 10.1038/s41598-020-62427-8
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.23 Å)
Structure validation

236620

PDB entries from 2025-05-28

PDB statisticsPDBj update infoContact PDBjnumon